NASDAQ:NCEL

NLS Pharmaceutics Q2 2026 Earnings Results & Report

NLS Pharmaceutics logo
$2.68 -0.07 (-2.55%)
As of 02:53 PM Eastern

NLS Pharmaceutics reported Q2 2026 earnings on September 18, 2026. The company reported EPS of -$0.48.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens

NLS Pharmaceutics EPS Results

Actual EPS
-$0.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NLS Pharmaceutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

NLS Pharmaceutics Q2 2026 Earnings FAQ

NLS Pharmaceutics (NASDAQ:NCEL) reported earnings of -$0.48 per share for Q2 2026. The report was announced on Friday, September 18, 2026.

NLS Pharmaceutics Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Der aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.
See More NLS Pharmaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NLS Pharmaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NLS Pharmaceutics and other key companies, straight to your email.

About NLS Pharmaceutics

NLS Pharmaceutics (NASDAQ:NCEL) was a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its drug-development programs included Quilience, an extended-release formulation of mazindol investigated for narcolepsy-related symptoms.

Following a business combination with Israeli biotechnology company Kadimastem, NLS Pharmaceutics changed its name to NewcelX Ltd. and began trading on Nasdaq under the symbol NCEL. The combined company’s programs include Kadimastem’s cell-therapy candidates AstroRx, developed for amyotrophic lateral sclerosis, and IsletRx, being developed for diabetes.

View NLS Pharmaceutics Profile